Blood cell-derived transplants at 40
February, 2026 is the 40th anniversary of the 1st publication of rapid recovery of bone marrow function after high-dose chemotherapy and infusion of an autologous blood- rather than a bone-marrow-derived graft. The recipient, a man with advanced Burkitt lymphoma, is in remission and alive. In the ne...
Salvato in:
| Autori principali: | , , , |
|---|---|
| Natura: | Article (Journal) |
| Lingua: | inglese |
| Pubblicazione: |
2026
|
| In: |
Bone marrow transplantation
Year: 2026, Volume: 61, Fascicolo: 6, Pages: 663-667 |
| ISSN: | 1476-5365 |
| DOI: | 10.1038/s41409-026-02865-6 |
| Accesso online: | Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41409-026-02865-6 Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41409-026-02865-6 
|
| Note sull'autore: | Anthony D. Ho, Peter Dreger, Christopher Juttner and Robert Peter Gale |
| Riassunto: | February, 2026 is the 40th anniversary of the 1st publication of rapid recovery of bone marrow function after high-dose chemotherapy and infusion of an autologous blood- rather than a bone-marrow-derived graft. The recipient, a man with advanced Burkitt lymphoma, is in remission and alive. In the next 40 years transplants of blood-derived progenitor cells have become the most common graft for auto- and allotransplants. The rapid hematopoietic recovery after blood cell-derived grafts is associated with fewer short-term complications and better outcomes in many settings compared with bone marrow-derived grafts but may be associated with more graft-versus-host disease (GvHD) after allotransplants. Using blood-derived grafts also reduced costs, enabled the development of cell-based immune therapy and in vitro manipulation of blood-derived cells for gene and chimeric antigen receptor (CAR)-T-cell therapies. |
|---|---|
| Descrizione del documento: | Online veröffentlicht: 14. April 2026 Gesehen am 17.06.2026 |
| Descrizione fisica: | Online Resource |
| ISSN: | 1476-5365 |
| DOI: | 10.1038/s41409-026-02865-6 |